Investing

James Wolf Ups Stake in Enzo, May Seek Board Seat

Fintel reports that James Wolf has filed a 13D/A form with the SEC disclosing ownership of 4,942,400 shares of Enzo Biochem, Inc. (ENZ). This represents 10.14% of the company.

In is previous filing dated November 23, 2022 Wolf reported 4,168,500 shares and 8.56% of the company, an increase in shares of 18.57% and an increase in total ownership of 1.58% (calculated as current – previous percent ownership

Wolf said in the filing he may nominate himself for election as a director of the Company at the next annual meeting of shareholders if he is not nominated or approved by the Board of Directors.

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

What are large shareholders doing?

Harbert Fund Advisors, Inc. holds 5,175,913 shares representing 10.62% ownership of the company. No change in the last quarter.

Renaissance Technologies Llc holds 2,909,664 shares representing 5.97% ownership of the company. In it’s prior filing, the firm reported owning 3,016,164 shares, representing a decrease of 3.66%. The firm increased its portfolio allocation in ENZ by 24.21% over the last quarter.

Roumell Asset Management, LLC holds 2,390,211 shares representing 4.91% ownership of the company. No change in the last quarter.

VIEX Capital Advisors, LLC holds 1,334,479 shares representing 2.74% ownership of the company. In it’s prior filing, the firm reported owning 1,536,857 shares, representing a decrease of 15.17%. The firm increased its portfolio allocation in ENZ by 14.45% over the last quarter.

Fuller & Thaler Asset Management, Inc. holds 971,010 shares representing 1.99% ownership of the company. In it’s prior filing, the firm reported owning 957,485 shares, representing an increase of 1.39%. The firm increased its portfolio allocation in ENZ by 14.23% over the last quarter.

Fund Sentiment

There are 91 funds or institutions reporting positions in Enzo Biochem, Inc.. This is a decrease of 12 owner(s) or 11.65%.

Average portfolio weight of all funds dedicated to Enzo Biochem, Inc. is 0.3169%, an increase of 20.3050%. Total shares owned by institutions decreased in the last three months by 3.34% to 23,764,544 shares.

This article originally appeared on Fintel

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.